Clinical trials: Dementia of Alzheimer Type
Caregiver Stress, Dementia
A Study of Caregiver Connections Via Technology in Dementia
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes.
- Conditions
- Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia
- Trial name
- NCT05779839
- Testing
- Algorithm, Random Match
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer Disease, Dementia
Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation
Globally, >47M individuals live with dementia, with new incidence of 7.7M annually. Medication mismanagement is one of the most common and concerning risk factors in people with dementia (PwD), as it leads to undertreatment…
- Conditions
- Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT06691256
- Testing
- HiDO-ALZ
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HiDO Technologies
Dementia of Alzheimer Type, Alzheimer Disease
Telehealth-enabled Integrated Palliative Care for People With Dementia
In prior work, this team developed a telehealth primary care model (TIPC), designed in close partnership with patients and clinicians to address a widespread increase in telehealth use during the COVID-19 pandemic.
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Frontotemporal Degeneration, Lewy Body Dementia
- Trial name
- IBC (NCT05524181)
- Testing
- Telehealth Integrated Primary Care (TIPC)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Thomas Jefferson University
Alzheimer's Disease
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
- Trial name
- NCT02185053
- Testing
- CPC-201
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Mild Dementia
Improving Everyday Task Performance Through Repeated Practice in Virtual Reality.
There are very few effective interventions that promote functional independence in people with Alzheimer's disease (AD) and related dementias.
- Conditions
- Alzheimer Disease, Mild Dementia, Mild Cognitive Impairment, Dementia
- Trial name
- VKI (NCT04315337)
- Testing
- Virtual Kitchen Training
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Temple University
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842816
- Testing
- ST101
- Where
- 30 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimers Disease, Dementia
University of Central Florida Music Study
The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes.
- Conditions
- Alzheimers Disease, Dementia, Dementia Alzheimer Type
- Trial name
- NCT07306065
- Testing
- Music intervention
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Alzheimer Disease
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00103649
- Testing
- xaliproden (SR57746A)
- Where
- 121 sites in United States, Canada
- Volunteers
- 1,306 people
- Sponsor
- Sanofi
Alzheimer Disease, Dementia, Alzheimer Type
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to…
- Trial name
- NCT02322021
- Testing
- E2609
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment
The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment
BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill…
- Trial name
- MeDi-SUPOL (NCT06705738)
- Testing
- SUPOL, Dietary Pattern: MeDi
- Where
- 2 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Aristotle University Of Thessaloniki
Dementia, Dementia, Mixed
Uppsala-Dalarna Dementia and Gait Project
UDDGait™ is a multidisciplinary research project with the overreaching goal of providing an aid for early identification of cognitive impairment and risk of dementia development, thereby providing a basis for adequate symptom…
- Conditions
- Dementia, Dementia, Mixed, Dementia Senile, Dementia of Alzheimer Type
- Trial name
- UDDGait™ (NCT05893524)
- Testing
- Timed Up-and-Go (TUG single-task), Timed Up-and-Go dual-task (TUGdt), Clinical functional assessment
- Where
- 2 sites in Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Dalarna University
Alzheimer Disease, Dementia
Development of NIC5-15 in the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
- Trial name
- NCT00470418
- Testing
- NIC5-15
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease, Obesity
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
Background: Insulin removes sugar from the blood to use for energy. Insulin resistance means that cells may not respond to insulin normally. It can lead to serious diseases.
- Conditions
- Alzheimer's Disease, Obesity, Diabetes Mellitus
- Trial name
- NCT02460783
- Testing
- Boost (R) 5-2 diet, Healthy Living Diet
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203320
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Alzheimer Disease, Dementia, Alzheimer Type
Deep Brain Stimulation for Alzheimer's Disease
Background: Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional brain circuits. The safety and preliminary efficacy of nucleus basalis of Meynert (NBM)-DBS in Alzheimer's disease (AD) is proved in a…
- Conditions
- Alzheimer Disease, Dementia, Alzheimer Type, Deep Brain Stimulation
- Trial name
- NCT03959124
- Testing
- Deep brain stimulation, Best medical treatment for Alzheimer's disease
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Buddhist Tzu Chi General Hospital
Alzheimer's Disease, Dementia, Alzheimer Type
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
- Trial name
- NCT00099242
- Testing
- rivastigmine transdermal patch
- Where
- 75 sites in United States, Chile and 19 more
- Volunteers
- 1,040 people
- Sponsor
- Novartis Pharmaceuticals